Literature DB >> 20463388

RNAi nanomedicines: challenges and opportunities within the immune system.

Shiri Weinstein1, Dan Peer.   

Abstract

RNAi, as a novel therapeutic modality, has an enormous potential to bring the era of personalized medicine one step further from notion into reality. However, delivery of RNAi effector molecules into their target tissues and cells remain extremely challenging. Major attempts have been made in recent years to develop sophisticated nanocarriers that could overcome these hurdles. This review will present the recent progress with the challenges and opportunities in this emerging field, focusing mostly on the in vivo applications with special emphasis on the strategies for RNAi delivery into immune cells.

Mesh:

Substances:

Year:  2010        PMID: 20463388     DOI: 10.1088/0957-4484/21/23/232001

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  18 in total

1.  Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Authors:  Jagjeet K Kang; Alberto Malerba; Linda Popplewell; Keith Foster; George Dickson
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

Authors:  David N Nguyen; Kerry P Mahon; Ghania Chikh; Phillip Kim; Hattie Chung; Alain P Vicari; Kevin T Love; Michael Goldberg; Steve Chen; Arthur M Krieg; Jianzhu Chen; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

3.  Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.

Authors:  Shanthi Ganesh; Arun K Iyer; David V Morrissey; Mansoor M Amiji
Journal:  Biomaterials       Date:  2013-02-11       Impact factor: 12.479

Review 4.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

5.  Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.

Authors:  Shiri Weinstein; Itai A Toker; Rafi Emmanuel; Srinivas Ramishetti; Inbal Hazan-Halevy; Daniel Rosenblum; Meir Goldsmith; Avigdor Abraham; Ohad Benjamini; Osnat Bairey; Pia Raanani; Arnon Nagler; Judy Lieberman; Dan Peer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-23       Impact factor: 11.205

Review 6.  High-density lipoproteins for the systemic delivery of short interfering RNA.

Authors:  Kaylin Marie McMahon; Colby Shad Thaxton
Journal:  Expert Opin Drug Deliv       Date:  2013-12-09       Impact factor: 6.648

Review 7.  Lipoproteins and lipoprotein mimetics for imaging and drug delivery.

Authors:  C Shad Thaxton; Jonathan S Rink; Pratap C Naha; David P Cormode
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

Review 8.  Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems.

Authors:  Rami Alzhrani; Hashem O Alsaab; Alex Petrovici; Ketki Bhise; Kushal Vanamala; Samaresh Sau; Matthew J Krinock; Arun K Iyer
Journal:  Drug Discov Today       Date:  2019-11-20       Impact factor: 7.851

9.  Specific Jak3 Downregulation in Lymphocytes Impairs γc Cytokine Signal Transduction and Alleviates Antigen-driven Inflammation In Vivo.

Authors:  Alicia G Gómez-Valadés; María Llamas; Sílvia Blanch; José C Perales; Juan Román; Lluís Gómez-Casajús; Cristina Mascaró
Journal:  Mol Ther Nucleic Acids       Date:  2012-09-04       Impact factor: 10.183

Review 10.  Harnessing RNAi nanomedicine for precision therapy.

Authors:  Dan Peer
Journal:  Mol Cell Ther       Date:  2014-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.